Unavailable · 22.10.2026
Supply shortage Austria: Etibi 500 mg - Ampullen – Unavailable, 22.10.2026 · ENR Zulassungsnummer 15737
Affected country: Austria · Reported period: 10.08.2026 – 18.12.2026 · Active ingredient: ETHAMBUTOL DIHYDROCHLORID
Active ingredients
Notice context
A supply shortage has been recorded for Etibi 500 mg - Ampullen in Austria. The stated reason is “Manufacturing capacity constraints”. The notice concerns the active ingredient ETHAMBUTOL DIHYDROCHLORID and is not identified as hospital-relevant.
This information describes the reported supply status and is not medical or pharmaceutical treatment advice. Availability, alternatives and further measures must be assessed for each individual case by the responsible pharmaceutical market participants.
Official shortage notice for Austria. Responsibility and update procedures follow the information supplied by the relevant authority.
Check the official notice list →Implications for procurement and the supply chain
The notice for Etibi 500 mg - Ampullen is a supply signal concerning ETHAMBUTOL DIHYDROCHLORID in Austria. The published reason “Manufacturing capacity constraints” determines which data should be verified first.
For manufacturing or capacity constraints, the focus is on credible restart dates, available batches, qualified sources and the coverage of existing stock.
Once a lawful sourcing route is confirmed and buffer stock is required, our pharma warehouse in Cheb page explains receipt, stock control and picking.
Decision route for this supply case
- Confirm the notice, product identity, period and actual demand with the primary source and accountable market participants.
- Assess restart timing, available batches, qualified sources and a lawful bridging stock separately.
- Document release, stock status, GDP evidence, warehousing and transport process, and escalation responsibility.
Inter-Pharma can structure the B2B case, potential sourcing and warehousing routes, and operational implementation. Clinical decisions, regulatory permissibility, product release and actual availability remain with the accountable parties.
Request a structured supply review →Operational shortage resilience: GDP warehousing and pharmaceutical storage
For manufacturing shortages, an agreed restart stock for Etibi 500 mg - Ampullen can be received and distributed under control after release.
Inter-Pharma combines GDP-oriented pharmaceutical storage in Czechia with batch and expiry control, FEFO, stock status, picking and dispatch preparation in its own Cheb operation.
Because the product name may indicate a temperature-sensitive dosage form, the product specification and any 2–8 °C requirement are assessed project by project; this is not a blanket capacity commitment.
Operational checks for this notice
- Match product identity using PZN 0155406, active ingredient, strength, dosage form and pack.
- Confirm the reported status and the period 10.08.2026 to 18.12.2026 with the primary source and potential suppliers.
- Document demand, stock coverage, open orders and lawful alternative or sourcing routes for the specific case.
- Clarify temperature, batch, expiry, stock status, recipient authorisation and GDP evidence before cross-border supply.
Relevant services and specialist pages
The following B2B topics are particularly relevant when handling a shortage involving Etibi 500 mg - Ampullen: